Analysis of antiviral drugs consumption on the pharmaceutical market of ukraine which are used for pharmacotherapy in arvi patients
DOI:
https://doi.org/10.24959/ubphj.18.161Keywords:
ARVI, nomenclature of antiviral drugs, drug consumption, prices for drugsAbstract
Acute respiratory viral infections (ARVI) are the most common infectious diseases. Antiviral drugs (AD) are considered to be the main group for etiotropic treatment in pharmacotherapy complex of acute respiratory viral infection.
Aim. To study the assortment and consumption of AD on the pharmaceutical market of Ukraine for 2013-2017.
Materials and methods. The AD range analysis was carried out according to the information retrieval system “Pharmstandard” of the company “Morion”, consumption – by the indicator DDDs/1000 inhabitants/day.
Results and discussion. The most consumed antiviral drugs in 2013-2017 are inosine pranobex, rimantadine, umifenovir and other antiviral agents. The annual volume of ARVI patients requiring the use of antiviral agents covers from 21.95 % to 23.58 % of the population, and in fact, during the study period, antiviral agents for the treatment of acute respiratory viral infections with one 10-day course were used from 0.60 % to 0.85 % among the population of Ukraine.
Conclusions. Despite of the wide range of antiviral drugs in Ukraine, their consumption rates are very low, it may be caused by the high cost of treatment, insufficiently proven clinical efficacy and low frequency of appointment.
References
Bogomolov, B. P. (2007). Infektcionnye bolezni: neotlozhnoia diagnostika, lechenie, profilaktika. Moscow: Niudiamed, 653.
Romantcov, M. G., Sologub, T. V., Shuldiakova, O. G. (2007). Consilium medicum. Pediatriia, 2, 18–22.
Chernysheva, O. E. (2006). Zdorove rebenka, 3 (3), 8–12.
Selkova, E. P. (2007) Consilium medicum, 9, (1). Available at: http://www.consiliummedicum.com/article/8327
Smiian, O. I., Binda, T. P., Dmitrova, E. V., Sukharieva, V. A. (2013). Zhurnal klinichnykh ta eksperymentalnykh medychnykh doslidzhen, 1, (3), 328–336.
Golubovska, O. A., Skurba, A. V., Pechinka, A. M. (2012). Ukraina. Zdorovia natsii, 1, 129–139.
Yavorskyi, M. I. (2013). Visnyk sotsialnoi hihiieny ta orhanizatsii okhorony zdorovia Ukrainy, 4, 52–54.
Markova, T. P., Chuvirov, D. G. (2016). RMZh, 3, 171–176.
Cheshik, S. G., Vartanian, R. V. (2005). Novye lekarstvennye preparaty, 11, 37–44.
Savenkova, M. S. (2011). Lechashchii vrach, 3, 1–8.
Boriskin, Y., Leneva, I., Pecheur, E.–I., Polyak, S. (2008). Arbidol: A Broad–Spectrum Antiviral Compound that Blocks Viral Fusion. Current Medicinal
Chemistry, 15 (10), 997–1005. doi: 10.2174/092986708784049658
Kniazheskaia, N. P. (2015). RMZh, 18, 1116–1120.
Golebiowska–Wawrzyniak, M., Markiewicz, K., Kozar, A. et al. (2005). Immunological and clinical study on therapeutic efficiacy of inosine
pranobex. Pol. Merkuriusc. Lek., 19, 379–382.
Speirs, C. J. (2001). Isoprinosine tablets: Pharmacotoxicological Expert Report. Dublin: Newport, 39.
Isakov, V. A., Beliaeva, Т. V., Afanaseva, O. I. (2013). Voprosy sovremennoi pediatrii, 12 (1), 136–140.
Prohramnyi compleks «Apteka» kompanii «Morion». Available at: http://pharmbase.com.ua/ru/
Morozov, A. M., Yakovlevа, L. V., Stepanenko, A. V. et al. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo–terapevtychno–khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATS/DDD metodolohiia). Kharkiv: Styl–Yzdat, 34.
Iakovlieva, L. V., Mishchenko, O. Ya., Adonkina, V. Yu. (2017). Farmakoepidemiolohichni doslidzhennia obsiahiv spozhyvannia antyhipertenzyvnykh likarskykh zasobiv v Ukraini. Kharkiv: NUPh, 108.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
